Clinical Trials
15
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (15 trials with phase data)• Click on a phase to view related trials
Study of XP-8121 For the Treatment of Adult Subjects With Hypothyroidism
- First Posted Date
- 2023-04-21
- Last Posted Date
- 2025-07-03
- Lead Sponsor
- Xeris Pharmaceuticals
- Target Recruit Count
- 46
- Registration Number
- NCT05823012
- Locations
- 🇺🇸
ProSciento, Inc., Chula Vista, California, United States
🇺🇸Catalina Research Institute, L.L.C., Montclair, California, United States
🇺🇸Panax Clinical Research, LLC, Miami Lakes, Florida, United States
Phase 2, Randomized, Open-Label, Crossover, PD/PK Study of a Novel Pram-Insulin Co-Formulation in Adults With T1D
- Conditions
- Diabetes Mellitus, Type 1Insulin-dependent Diabetes Mellitus
- Interventions
- First Posted Date
- 2019-08-30
- Last Posted Date
- 2024-03-27
- Lead Sponsor
- Xeris Pharmaceuticals
- Target Recruit Count
- 18
- Registration Number
- NCT04074317
- Locations
- 🇺🇸
World Wide Clinical Trials, San Antonio, Texas, United States
Glucagon Ready-to-Use (RTU) for Prevention of Exercise-Induced Hypoglycemia During Aerobic Exercise in Adults With T1D
- Conditions
- Hypoglycemia
- Interventions
- Drug: Glugaon RTU Injection Without Insulin Pump ReductionOther: Vehicle for Glucagon RTU Injection With Insulin Pump Reduction
- First Posted Date
- 2019-02-15
- Last Posted Date
- 2023-08-25
- Lead Sponsor
- Xeris Pharmaceuticals
- Target Recruit Count
- 48
- Registration Number
- NCT03841526
- Locations
- 🇨🇦
LMC Clinical Research Inc, Toronto, Ontario, Canada
Glucagon Ready to Use (RTU) in Subjects With Hyperinsulinemic Hypoglycemia After Bariatric Surgery
- Conditions
- Hyperinsulinemic Hypoglycemia
- Interventions
- Other: Placebo
- First Posted Date
- 2018-12-10
- Last Posted Date
- 2020-05-21
- Lead Sponsor
- Xeris Pharmaceuticals
- Target Recruit Count
- 14
- Registration Number
- NCT03770637
- Locations
- 🇺🇸
University of Colorado-Denver, Aurora, Colorado, United States
🇺🇸Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸Joslin Diabetes Center, Boston, Massachusetts, United States
G-Pen Compared to Glucagen Hypokit for Severe Hypoglycemia Rescue in Adults With Type 1 Diabetes
- Conditions
- Insulin HypoglycemiaType 1 Diabetes MellitusSevere Hypoglycemia
- Interventions
- Drug: Novo Glucagon
- First Posted Date
- 2018-11-13
- Last Posted Date
- 2020-05-22
- Lead Sponsor
- Xeris Pharmaceuticals
- Target Recruit Count
- 132
- Registration Number
- NCT03738865
- Locations
- 🇺🇸
Diablo Clinical Research, Walnut Creek, California, United States
🇺🇸Atlanta Diabetes Associates, Atlanta, Georgia, United States
🇺🇸PPD-Las Vegas Clinical Research Unit, Las Vegas, Nevada, United States
- Prev
- 1
- 2
- 3
- Next